 BURLINGAME, Calif. DUBLIN LONDON--BUSINESS WIRE--Humanigen, Inc. Nasdaq: HGEN, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced today that Timothy E. Morris, COOCFO, will be presenting at the upcoming 2022 BIO CEO Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th. Hosted annually by the Biotechnology Innovation Organization BIO fo 